Hara, Junichi
Matsumoto, Kimikazu
Maeda, Naoko
Takahara-Matsubara, Mariko
Sugimoto, Saori
Goto, Hiroaki
Funding for this research was provided by:
An advisory board member of OHARA Pharmaceuticals and received consultancy fees from OHARA Pharmaceuticals
Dainippon Sumitomo Pharma
Lecture fees from Amgen Astellas BioPharma
Article History
Received: 5 August 2021
Revised: 15 June 2022
Accepted: 24 August 2022
First Online: 3 November 2022
Change Date: 8 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-022-01890-5
Competing interests
: This study was funded by Sumitomo Pharma Co., Ltd (formerly Sumitomo Dainippon Pharma Co., Ltd.). JH is an advisory board member of OHARA Pharmaceuticals and received consultancy fees from OHARA Pharmaceuticals. KM and NM declared no conflict of interest. MT and SS are employees of Sumitomo Pharma. HG received lecture fees from Amgen Astellas BioPharma.